Richmond Pharmacology’s New London Bridge unit offers unrivalled access to patient recruitment

Posted:
28
April 2017

Richmond Pharmacology has been settling into life in its New London Bridge Research Unit.

The new MHRA accredited unit has been actively running trials in its new surroundings since March 25th with excellent on-going patient feedback.

Our new facility is an early phase specialist unit, it is the fourth unit Richmond Pharmacology has opened and we believe it is our best to date. Richmond Pharmacology completely removed the existing facilities in the building and designed all the floors from scratch creating a better patient experience in the process. The new site has previously been used for conducting early Phase trials for more than 30 years.

It is in an ideal location embedded in the King’s College University and teaching hospital campus."The opening of our new research facility, at what was formerly known as the Guy’s Drug Research Unit, is an exciting addition to our research capability, and will help us to provide the best possible support for our clients in their drive to increase the effectiveness and cost efficiency of developing new drugs and taking them to market."

Richmond Pharmacology CEO, Dr Jorg Taubel.Our integrated, MHRA licensed clinical trials pharmacy is staffed by an experienced and dedicated team, supervised by two expert QPs providing quality and flexible service, GMP advice and regulatory support to our clients.Located in centre of London, within close walking distance to key transport links, museums, historic attractions and all that London has to offer, Richmond believes the location will offer unrivalled access to patent recruitment enabling Richmond to maintain its position as Market Leaders in Combined Adaptive Early Phase Trials.

Latest news

Upcoming Event

ACCP 2020, Translating Clinical Pharmacology Research into Patient-centered Care

21 - 23 September 2020
Dr. Jorg Taubel will be presenting posters that explore the subjects of cardiac health and diabetes.
View event

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

August 17, 2020
Richmond Pharmacology early phase drug development update.
Read more